What they say

China Daily | Updated: 2019-11-08 08:34

The floor space of the medical equipment and healthcare products hall at the second CIIE is significantly expanded, indicating a growing enthusiasm from multinational pharmaceuticals and healthcare companies for the Chinese market. Novartis will show how it is expanding access to medicines by actively participating in the negotiations of the country's National Reimbursement Drug List, providing high-quality generic drugs and various patient assistance programs. As a Swiss company, we also hope to leverage this expo to further strengthen exchange between China and Switzerland.

Yin Xudong, president of Novartis Group (China)

Over the recent years, China has introduced many reforms to accelerate approval of innovative medicines and as well as expanding access by including high value drugs in the National Reimbursement Drug List. Further opening up in the healthcare sector fosters business growth, and more importantly, it benefits the Chinese people by granting access to most advanced medicines to address critical illnesses such as cancer. Roche has strong presence at CIIE because it is not only a great platform to showcase our new advancements in personalized healthcare, it also facilitates collaborations within and across industries, including those between enterprises and the government and those among enterprises. We believe that CIIE will help foster a favorable global ecosystem for innovation in the future.

Hong Chow, CEO of Roche Pharmaceuticals China

We have seen a promising market in China to raise the public awareness of health, guided by the country's Healthy China 2030 Initiative. The consumption ability of Chinese customers is enhancing. Especially the young generation and the middle-income customers, they care more about their health now and in the future, which drives their consumption in healthcare section, including healthy food and exercise.